FLOW Trial: Semaglutide and 24% Fewer Kidney Events The first dedicated GLP-1 kidney-outcomes trial in type 2 diabetes and CKD. d [Internet]. 2026 Jul. 7 [cited 2026 Jul. 28];4(20):40-1. Available from: https://thediabzen.com/index.php/d/article/view/63